Le Lézard

FDA Grants Priority Review To Genentech's Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to a supplemental ...
The Manila Times

FDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)

The filing application is based on improvements seen across key efficacy endpoints from the global phase III SatraGO-1 and SatraGO-2 studies, including proptosis (bulging eyes) and diplopia (double ...
Le Lézard

DRI Healthcare Comments on Viridian's FDA Approval and Launch of Lumvoatm (veligrotug-vvze)

DRI Healthcare Trust ("DRI Healthcare") today commented on Viridian Therapeutics, Inc.'s ("Viridian") recently announced ...